Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form - PubMed (original) (raw)
Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form
Abdulkader Obari et al. Endocr Pathol. 2008 Summer.
Abstract
Pituitary adenomas producing almost exclusively growth hormones (GH) have been ultrastructurally classified into two distinct types: densely granulated somatotroph (DG) adenomas and sparsely granulated (SG) adenomas. Fibrous body (FB), an intracytoplasmic globular aggregation of cytokeratin (CK) filaments, is a hallmark of SG adenomas. Under light microscope, FB could be identified by CK immunohistochemistry as a dot-pattern immunoreaction versus a perinuclear pattern for cells without FB. However, it has been noted that numerous adenomas contain mixed populations of the two patterns. To clarify clinicopathological characteristics of the adenomas with mixed populations ("intermediate type" adenomas) and to confirm clinicopathological differences between strictly defined DG-type and SG-type adenomas, we performed this study on 104 GH cell adenomas. Having segregated "intermediate-type" adenomas (26 cases), we found significant differences between typical DG-type (47 cases) and SG-type adenomas (31 cases); SG-type adenomas had younger ages (44 vs. 50), higher frequency of macroadenomas (86% vs. 58%), invasiveness (65% vs. 38%), advanced grades (3 or 4) in Knosp's classification (50% vs. 24%), and weaker immunoreaction for GH, beta-TSH, alpha-subunit, E-cadherin, and beta-catenin. Clinicopathological characteristics of "intermediate-type" adenomas were identical to those of DG-type adenomas. These findings confirm that SG-type adenoma is a distinct section of GH cell adenomas with special properties and biological behavior, and suggest that intermediate-phenotype adenomas are enrolled in DG-type adenomas. Special properties and biological behavior of SG-type adenomas may appear after the majority of tumor cells possess a fully developed fibrous body.
Similar articles
- Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly.
Swanson AA, Erickson D, Donegan DM, Jenkins SM, Van Gompel JJ, Atkinson JLD, Erickson BJ, Giannini C. Swanson AA, et al. Pituitary. 2021 Apr;24(2):192-206. doi: 10.1007/s11102-020-01096-2. Epub 2020 Oct 19. Pituitary. 2021. PMID: 33074402 - Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology.
Yamada S, Aiba T, Sano T, Kovacs K, Shishiba Y, Sawano S, Takada K. Yamada S, et al. Neurosurgery. 1993 Jul;33(1):20-7. doi: 10.1227/00006123-199307000-00003. Neurosurgery. 1993. PMID: 7689191 - Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.
Buurman H, Saeger W. Buurman H, et al. Eur J Endocrinol. 2006 May;154(5):753-8. doi: 10.1530/eje.1.02107. Eur J Endocrinol. 2006. PMID: 16645024 - Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas.
Sano T, Rong QZ, Kagawa N, Yamada S. Sano T, et al. Front Horm Res. 2004;32:127-32. doi: 10.1159/000079041. Front Horm Res. 2004. PMID: 15281343 Review. - Growth hormone-secreting adenomas: pathology and cell biology.
Lopes MB. Lopes MB. Neurosurg Focus. 2010 Oct;29(4):E2. doi: 10.3171/2010.7.FOCUS10169. Neurosurg Focus. 2010. PMID: 20887127 Review.
Cited by
- Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly.
Swanson AA, Erickson D, Donegan DM, Jenkins SM, Van Gompel JJ, Atkinson JLD, Erickson BJ, Giannini C. Swanson AA, et al. Pituitary. 2021 Apr;24(2):192-206. doi: 10.1007/s11102-020-01096-2. Epub 2020 Oct 19. Pituitary. 2021. PMID: 33074402 - Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study.
Lasolle H, Ferriere A, Vasiljevic A, Eimer S, Nunes ML, Tabarin A. Lasolle H, et al. Endocr Connect. 2019 Oct;8(10):1383-1394. doi: 10.1530/EC-19-0332. Endocr Connect. 2019. PMID: 31518993 Free PMC article. - Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly.
Heck A, Emblem KE, Casar-Borota O, Bollerslev J, Ringstad G. Heck A, et al. Endocrine. 2016 May;52(2):333-43. doi: 10.1007/s12020-015-0766-8. Epub 2015 Oct 16. Endocrine. 2016. PMID: 26475495 - Shape and texture analyses based on conventional MRI for the preoperative prediction of the aggressiveness of pituitary adenomas.
Wang X, Dai Y, Lin H, Cheng J, Zhang Y, Cao M, Zhou Y. Wang X, et al. Eur Radiol. 2023 May;33(5):3312-3321. doi: 10.1007/s00330-023-09412-7. Epub 2023 Feb 4. Eur Radiol. 2023. PMID: 36738323
References
- Arch Pathol Lab Med. 1985 Jun;109(6):505-8 - PubMed
- Pathol Int. 2001 Jul;51(7):532-42 - PubMed
- Endocr Pathol. 2002 Winter;13(4):341-51 - PubMed
- J Clin Endocrinol Metab. 2005 Nov;90(11):6290-5 - PubMed
- Neurosurgery. 1993 Oct;33(4):610-7; discussion 617-8 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials